JP2022516660A5 - - Google Patents

Info

Publication number
JP2022516660A5
JP2022516660A5 JP2021539621A JP2021539621A JP2022516660A5 JP 2022516660 A5 JP2022516660 A5 JP 2022516660A5 JP 2021539621 A JP2021539621 A JP 2021539621A JP 2021539621 A JP2021539621 A JP 2021539621A JP 2022516660 A5 JP2022516660 A5 JP 2022516660A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
fusion antibody
seq
glb1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516660A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012549 external-priority patent/WO2020146359A1/en
Publication of JP2022516660A publication Critical patent/JP2022516660A/ja
Publication of JP2022516660A5 publication Critical patent/JP2022516660A5/ja
Pending legal-status Critical Current

Links

JP2021539621A 2019-01-08 2020-01-07 ＣＮＳにおけるガラクトシダーゼβ－１活性を増加させるための方法および組成物 Pending JP2022516660A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789953P 2019-01-08 2019-01-08
US62/789,953 2019-01-08
PCT/US2020/012549 WO2020146359A1 (en) 2019-01-08 2020-01-07 Methods and compositions for increasing galactosidase beta-1 activity in the cns

Publications (2)

Publication Number Publication Date
JP2022516660A JP2022516660A (ja) 2022-03-01
JP2022516660A5 true JP2022516660A5 (enExample) 2023-01-06

Family

ID=71521947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539621A Pending JP2022516660A (ja) 2019-01-08 2020-01-07 ＣＮＳにおけるガラクトシダーゼβ－１活性を増加させるための方法および組成物

Country Status (4)

Country Link
US (2) US20210403584A1 (enExample)
EP (1) EP3908611A4 (enExample)
JP (1) JP2022516660A (enExample)
WO (1) WO2020146359A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
EP4526351A2 (en) * 2022-05-16 2025-03-26 City of Hope Anti-cd84 antibodies and uses thereof
JP2025533863A (ja) * 2022-10-12 2025-10-09 ノベルファーマ株式会社 Ｇｍ１ガングリオシド症又はモルキオ症候群ｂ型の治療、予防又は改善用薬学的組成物及びその投与方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082224A1 (en) * 1997-01-14 2002-06-27 Douglas J. Jolly Non-immunogenic prodrugs and selectable markers for use in gene therapy
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US7932032B2 (en) * 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
CA2641070C (en) * 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
WO2008051854A2 (en) * 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
WO2010108048A2 (en) * 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
EP2764119A2 (en) * 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER

Similar Documents

Publication Publication Date Title
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2022518392A5 (enExample)
JP2021508449A5 (enExample)
JP2021512881A5 (enExample)
JP2023504914A5 (enExample)
JP2013537416A5 (enExample)
JP2016525545A5 (enExample)
JP2015509097A5 (enExample)
JP2010539921A5 (enExample)
JP7449092B2 (ja) 血液脳関門移動化合物及びその使用
AU2012308636B2 (en) Glucagon-like peptide-2 compositions and methods of making and using same
JP2008500373A5 (enExample)
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2021512159A5 (enExample)
JP2008515889A5 (enExample)
JP2008521426A5 (enExample)
JP2021531732A5 (enExample)
JP2023552462A5 (enExample)
JP2024501771A5 (enExample)
US20240270797A1 (en) Coronavirus neutralizing compositions and associated methods
TW202515905A (zh) 用於遞送顆粒蛋白穿過血腦障壁之化合物
JP2017524675A5 (enExample)
JP2026077893A (ja) 医薬製剤
JP2026047374A (ja) 医薬製剤
JP2021533167A5 (enExample)